CCL

Összesen 3 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM077036
035-os BibID:(WoS)000458934000210 (Scopus)85061291471
Első szerző:Bombicz Mariann (gyógyszerész)
Cím:The Drug Candidate BGP-15 Delays the Onset of Diastolic Dysfunction in the Goto-Kakizaki Rat Model of Diabetic Cardiomyopathy / Bombicz Mariann, Priksz Daniel, Gesztelyi Rudolf, Kiss Rita, Hollos Nora, Varga Balazs, Nemeth Jozsef, Toth Attila, Papp Zoltan, Szilvassy Zoltan, Juhasz Bela
Dátum:2019
ISSN:1420-3049
Megjegyzések:Background and Aims: Diabetic cardiomyopathy (DCM) is an emerging problem worldwide due to an increase in the incidence of type 2 diabetes. Animal studies have indicated that metformin and pioglitazone can prevent DCM partly by normalizing insulin resistance, and partly by other, pleiotropic mechanisms. One clinical study has evidenced the insulin-senzitizing effect of the drug candidate BGP-15, along with additional animal studies that have confirmed its beneficial effects in models of diabetes, muscular dystrophy and heart failure, with the drug affecting chaperones, contractile proteins and mitochondria. Our aim was to investigate whether the inzulin-senzitizer BGP-15 exert any additive cardiovascular effects compared to metformin or pioglitazone, using Goto-Kakizaki (GotoK) rats. Methods: Rats were divided into five groups: (I) healthy control (Wistar), (II) diseased (GotoK), and GotoK rats treated with: (III) BGP-15, (IV) metformin, and (V) pioglitazone, respectively, for 12 weeks. Metabolic parameters and insulin levels were determined at the endpoint. Doppler echocardiography was carried out to estimate diabetes-associated cardiac dysfunction. Thoracotomy was performed after the vascular status of rats was evaluated using an isolated aortic ring method. Furthermore, western blot assays were carried out to determine expression or phosphorylation levels of selected proteins that take part in myocyte relaxation. Results: BGP-15 restored diastolic parameters (e·/a·, E/e·, LAP, E and A wave) and improved Tei-index compared to untreated GotoK rats. Vascular status was unaffected by BGP-15. Expression of sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2a) and phosphodiesterase 9A (PDE9A) were unchanged by the treatments, but the phosphorylation level of vasodilator-stimulated phosphoprotein (VASP) and phospholamban (PLB) increased in BGP-15-treated rats, in comparison to GotoK. Conclusions: Even though the BGP-15-treatment did not interfere significantly with glucose homeostasis and vascular status, it considerably enhanced diastolic function, by affecting the SERCA/phospholamban pathway in GotoK rats. Although it requires further investigation, BGP-15 may offer a new therapeutic approach in DCM.
Tárgyszavak:Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
BGP-15
diastolic dysfunction
type 2 diabetes
Goto-Kakizaki
echocardiography
Megjelenés:Molecules. - 24 : 3 (2019), p. 1-18. -
További szerzők:Priksz Dániel (1989-) (farmakológus) Gesztelyi Rudolf (1969-) (kísérletes farmakológus) Kiss Rita (1974-) (laboratóriumi diagnosztika szakorvos) Hollós Nóra (1995-) (hallgató) Varga Balázs (1984-) (kísérletes farmakológus) Németh József (1954-) (vegyész, analitikus) Tóth Attila (1971-) (biológus) Papp Zoltán (1965-) (kardiológus, élettanász) Szilvássy Zoltán (1957-) (belgyógyász, farmakológus, klinikai farmakológus) Juhász Béla (1978-) (kísérletes farmakológus)
Pályázati támogatás:GINOP-2.3.4-15-2016-00002
GINOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM086205
035-os BibID:(WoS)000553858800078 (Scopus)85085910076
Első szerző:Hegedűs Csaba (Molekuláris biológus, Cera-Med Kft. Debrecen)
Cím:SIRT1 Activation by Equisetum Arvense L. (Horsetail) Modulates Insulin Sensitivity in Streptozotocin Induced Diabetic Rats / Csaba Hegedűs, Mariana Muresan, Andrea Badale, Mariann Bombicz, Balázs Varga, Anna Szilágyi, Dávid Sinka, Ildikó Bácskay, Mihaela Popoviciu, Ioan Magyar, Mária Magdolna Szarvas, Erzsébet Szőllősi, József Németh, Zoltán Szilvássy, Annamária Pallag, Rita Kiss
Dátum:2020
ISSN:1420-3049
Megjegyzések:Equisetum arvense L., commonly known as field horsetail is a perennial fern of which extracts are rich sources of phenolic compounds, flavonoids, and phenolic acids. Activation of SIRT1 that was shown to be involved in well-known signal pathways of diabetic cardiomyopathy has a protective effect against oxidative stress, inflammatory processes, and apoptosis that are the basis of diseases such as obesity, diabetes mellitus, or cardiovascular diseases. The aim of our study was to evaluate the antidiabetic and cardioprotective effects of horsetail extract in streptozotocin induced diabetic rats. METHODS: Diabetes was induced by a single intraperitoneal injection of 45 mg/kg streptozotocin. In the control groups (healthy and diabetic), rats were administered with vehicle, whilst in the treated groups, animals were administered with 50, 100, or 200 mg/kg horsetail extract, respectively, for six weeks. Blood glucose levels, glucose tolerance, and insulin sensitivity were determined, and SIRT1 levels were measured from the cardiac muscle. RESULTS: The horsetail extract showed moderate beneficial changes in blood glucose levels and exhibited a tendency to elevate SIRT1 levels in cardiomyocytes, furthermore a 100 mg/kg dose also improved insulin sensitivity. CONCLUSIONS: Altogether our results suggest that horsetail extract might have potential in ameliorating manifested cardiomyopathy acting on SIRT1.
Tárgyszavak:Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Molecules. - 25 : 11 (2020), p. 2541-2561. -
További szerzők:Muresan, Mariana Badale, Andrea (1986-) (gyógyszerész) Bombicz Mariann (1987-) (gyógyszerész) Varga Balázs (1984-) (kísérletes farmakológus) Szilágyi Anna Tünde (1981-) Sinka Dávid Zsolt (1991-) (gyógyszerész) Bácskay Ildikó (1969-) (gyógyszerész, gyógyszertechnológus) Popoviciu, Mihaela Magyar, Ioan Szarvas Mária Magdolna (1989-) (élelmiszeripari mérnök) Szőllősi Erzsébet (1983-) (biológus) Németh József (1954-) (vegyész, analitikus) Szilvássy Zoltán (1957-) (belgyógyász, farmakológus, klinikai farmakológus) Pallag Annamária Kiss Rita (1974-) (laboratóriumi diagnosztika szakorvos)
Pályázati támogatás:NKFIH1150-6/2019
Egyéb
GINOP-2.3.2-15-2016-00043
GINOP
EFOP-3.6.2-16-2017-00009
EFOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM085888
035-os BibID:(cikkazonosító)2124 (scopus)85082286798 (wos)000529890200220
Első szerző:Wachal Zita
Cím:Retinoprotection by BGP-15, a Hydroximic Acid Derivative, in a Type II Diabetic Rat Model Compared to Glibenclamide, Metformin, and Pioglitazone / Wachal Zita, Bombicz Mariann, Priksz Dániel, Hegedűs Csaba, Kovács Diána, Szabó Adrienn Mónika, Kiss Rita, Németh József, Juhász Béla, Szilvássy Zoltán, Varga Balázs
Dátum:2020
ISSN:1661-6596 1422-0067
Megjegyzések:High blood glucose and the consequential ischemia-reperfusion (I/R) injury damage vessels of the retina, deteriorating its function, which can be clearly visualized by electroretinography (ERG). The aim of the present study was to evaluate the possible retinoprotective effects of systemic BGP-15, an emerging drug candidate, in an insulin resistant animal model, the Goto-Kakizaki rat, and compare these results with well-known anti-diabetics such as glibenclamide, metformin, and pioglitazone, which even led to some novel conclusions about these well-known agents. Experiments were carried out on diseased animal model (Goto-Kakizaki rats). The used methods include weight measurement, glucose-related measurements?like fasting blood sugar analysis, oral glucose tolerance test, hyperinsulinemic euglycemic glucose clamp (HEGC), and calculations of different indices from HEGC results?electroretinography and Western Blot. Beside its apparent insulin sensitization, BGP-15 was also able to counteract the retina-damaging effect of Type II diabetes comparable to the aforementioned anti-diabetics. The mechanism of retinoprotective action may include sirtuin 1 (SIRT1) and matrix metalloproteinase 9 (MMP9) enzymes, as BGP-15 was able to elevate SIRT1 and decrease MMP9 expression in the eye. Based on our results, this emerging hydroximic acid derivative might be a future target of pharmacological developments as a potential drug against the harmful consequences of diabetes, such as diabetic retinopathy.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
electroretinography (ERG)
Goto-Kakizaki rat
pioglitazone
metformin
glibenclamide
BGP
diabetic retinopathy
Megjelenés:International Journal Of Molecular Sciences. - 21 : 6 (2020), p. 1-19. -
További szerzők:Bombicz Mariann (1987-) (gyógyszerész) Priksz Dániel (1989-) (farmakológus) Hegedűs Csaba (1983-) (Molekuláris biológus, Cera-Med Kft. Debrecen) Kovács Diána Klára (1985-) (Molekuláris biológus) Szabó Adrienn Mónika (1982-) (orvos) Kiss Rita (1974-) (laboratóriumi diagnosztika szakorvos) Németh József (1954-) (vegyész, analitikus) Juhász Béla (1978-) (kísérletes farmakológus) Szilvássy Zoltán (1957-) (belgyógyász, farmakológus, klinikai farmakológus) Varga Balázs (1984-) (kísérletes farmakológus)
Pályázati támogatás:GINOP-2.3.2-15-2016-00043
GINOP
EFOP-3.6.3-VEKOP-16-2017-00009
EFOP
NKFIH-1150-6/2019
NKFIH
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1